ImetelChat

(thanks to hiprock) Novel Efficient Cell-Penetrating, Peptide-Mediated Strategy for Enhancing Telomerase Inhibitor Oligonucleotides. A. Muñoz-Alarcón, J. Eriksson (Department of Neurochemistry, Stockholm University , Stockholm, Sweden) Ü. Langel (Laboratory of Molecular Biotechnology, Institute of T...

We can start a new topic on this CLL history.

Very good point, that's what I was thinking too. My conclusion is that they must see a way of improving the results. The Mayo study plays an important role in that, I believe. Dr.T. for sure is sharing detailed info on the Mayo study with JnJ.

Forgot the link. Here it is:
http://www.fool.com/investing/general/2 ... lnk0000004

Motley Fool, March 18, 2016 3 Biotech Stocks to Buy on Sale The broader market has mostly rebounded from its early 2016 tumble. The biotech sector hasn't, and our contributors see some bargains available in it now. Sean Williams about Geron: There are plenty of profitable biotech stocks on sale give...

Sargasso: the paranoia remark was not personal. Sorry if a made that impression. Investing in early biotech just asks for strong nerves and a steady course. Read the signs and make up your (own) mind... Since the JnJ partnership all the signs have been consistent. I bought during the hold, because o...

Sargasso, I don't think that this is something exceptional in business, certainly not in big business like this. At least, I am not the slightest bit of surprised about it. In my view there are various reasons: - imtelstat is a new drug, with a new MoA, in a very complex area of human biology. It is...

Here are some remarks from (our) Phil on the AACR abstracts, MoA etc.: "I have mentioned a few times that the reason I was so excited to have Geron partner with Janssen was that to me, while imetelstat and telomerase inhibition has massive potential, the drug has always needed better understanding, ...

Btw Sargasso: I agree that the CR's in the high risk Mayo MF patients are a probably a deeper kind of response than the high risk AML patients who benefited from Vyxeos. However, it is difficult to compare.

Hammie, it would be nice to have 10 years of exclusivity in my business, without having to pay any kind of license to anyone... In any case, it is worth while for Geron/JnJ to make sure they will keep the ODD status and maybe add some kind of fast track to it.

Parts of the Fool text seems familiar. Did they recycle on old article? CPXX: we should not forget that high risk AML is maybe even more agressive and difficult to treat than high risk MF although both are fatal for many. I am really looking forward to the AML trial, certainly after the promising da...

Here they are: Abstract Number: 2731 Presentation Title: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines Link: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=8843c2cd-002c-43b8-...

From Geron 10-K:

'In addition, ten years of market exclusivity is granted following drug product approval, meaning that another application for marketing authorization of a later similar medicinal product for the same therapeutic indication will generally not be approved in the EU.'

Bio, I meant is that what is fibrosis reversal as a marker for efficacy, is transfusion independence for MDS. But I agree, transfusion independence seems to be a less deep response than fibrosis reversal.

Thanks, very interesting slides! It shows Dr.T. being the Master of Mutations for MPN's. This is absolutely essential for getting a full grip on imetelstat and how it works with the different mutations. It is all about personalizing medicine. Good to know that he works closely with researchers from ...

Transfusion independence in MDS is a bit like reversal of fibrosis in MF. It says that there are two possible explanations for the relative meager depth of response: different disease biology or suboptimal drug dose. For the first they need to do further screening of mutational status in order to se...

Hi Sargasso, thanks for your excellent post. On the YMB this potential 'acquisition' is being used by many to create more uncertainty then is actually justified. Over 30 mln shares shorted represent a significant interest to keep pps low. So I am taking many of the concerns outed there with a lots o...

Tiny biotech Geron Corporation could see big gains from its collaboration with Johnson & Johnson. by Cory Renauer, MottleyFool, 8 march 2016 Developing and commercializing new cancer therapies is difficult for any organization. For a company as small Geron Corporation (NASDAQ: GERN), it's nearly im...

Telomerase Activity and Telomere Length in Human Benign Prostatic Hyperplasia Stem-like Cells and Their Progeny Implies the Existence of Distinct Basal and Luminal Cell Lineages Jayant K. Rane et al, European Urology, October 2015 / Published online: 09 October 2015 Abstract Benign prostatic hyperpl...

Tue, Mar 8, 2016, 6:19AM EST LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance shee...